Stay updated with breaking news from நஷ் ஓவேர்ஸ்திறீட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New studies mark an important advancement of Boehringer Ingelheim's cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on ....